SciSight Ecosystem
WoS SCIE Q4Scopus Q3SCImago #11,762CAS 4区Hybrid

Anti-Cancer Drugs

Abbreviation (ISO):ANTI-CANCER DRUG
Country: United States•WoS SCIE Quartile: Q4•Scopus SJR: 0.506•SCImago Rank: #11,762•Identifier (ISSN):0959-4973(Print)/1473-5741(Online)•Articles / Year: 141•Estimated Publication Fee (APC): $2,918 USD
Clarivate IF (2026)Q4
2
↓ -0.2

Leading citation impact metric from Clarivate Journal Citation Reports

JCR Release Date: 2026-06-17
H-Index (2021)
88

88 papers with at least that number of citations each

WoS: SCIE / JCRQ4
Self-Citation Rate0%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
141articles/year
27.32% Gold OA•90.04% Original Research

State Council for Professorship (HĐGSNN) Scoring

Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)

1.50pts
Latest Max Score
Estimated (Dec 26)
Scoring Basis: WoS Q3(IF: 2)

HĐGSNN Score History

By article publication year
YearMax ScoreEvaluation DetailsSource
20261.50đ
WoS Q3(IF: 2)
🔵 Computed
20251.50đ
WoS Q3(IF: 2.2)
🔵 Computed
20241.50đ
WoS Q3(IF: 1.8)
🔵 Computed
20231.50đ
WoS Q3(IF: 2.3)
🔵 Computed
20221.50đ
WoS Q3(IF: 2.389)
🔵 Computed
20211.50đ
WoS Q3(IF: 2.248)
🔵 Computed
20201.50đ
WoS Q3(IF: 2.26)
🔵 Computed
20191.50đ
WoS Q3(IF: 1.801)
🔵 Computed
20181.50đ
WoS Q3(IF: 1.869)
🔵 Computed

Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.

Aims & Scope

Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.

Topics Covered (Recognized by AI)
Biology92.7%Medicine91.1%Genetics90.4%Internal medicine85.7%Chemistry73.9%Biochemistry61.4%Cancer59.3%Surgery53.5%Chemotherapy45.8%Cancer research43.8%Pathology38.1%Pharmacology36.4%Organic chemistry34.3%Oncology31.5%Immunology29%In vitro28.5%Gene27.4%Apoptosis25.1%Cell culture23.9%Cell biology21.2%
Primary Research Areas

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #11,762Scopus Q3SCImago Profile
Scopus Coverage:1990-2026
Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicinePharmacology, Toxicology and Pharmaceutics
Scopus Citation Rank (SJR)Q3
0.506

Weighted prestige citation metric per document indexed in the Scopus database.

Tứ phân vị: Scopus Q3
Scopus H-Index (2025)
106

Measures cumulative publication volume and citation impact.

Scopus Database Indexed (2025)
Citations / Doc (2 years)
1.96

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$2,918 USD

Estimated Article Processing Charge for Open Access publication.

Chi phí ước tính / bài báo

Scopus 3-Year Publication & Citation Window

3-Year Citations1,033
3-Year Documents517
Citable Documents515

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate46.0%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

OncologyQ3
PharmacologyQ3
Pharmacology (medical)Q3
Cancer ResearchQ4

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
4区 (Zone 4)Medicine
Minor Category (Specific Field):
4区ONCOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Publisher Review Speed
Updating
Average time to first editorial decision
Online Publication Speed
Updating
Time from acceptance to online publication
Official Acceptance Rate
Updating
Manuscript acceptance rate confirmed by the publisher
Open Access Model
Hybrid
OA publishing option or traditional subscription
Publisher
Lippincott Williams and Wilkins Ltd.
Publication Language
English
Frequency
Monthly
Founding Year
1990
Editorial Address
LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621
Indexing & Databases
SCIEScopusPubMed

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
CategoryIndexRankQuartile
ONCOLOGY
JCRSCIE
250/333Q4
PHARMACOLOGY & PHARMACY
JCRSCIE
249/356Q3
ONCOLOGY
JCISCIE
196/333Q3
PHARMACOLOGY & PHARMACY
JCISCIE
207/356Q3

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
YearImpact FactorArticles / YearTotal Citations
2026—4310
20252.2120195
20241.8106355
20232.385464
20222.3892061,595
20212.2482392,377
20202.261461,809
20191.8011402,018
20181.8691452,431
2017—1182,752
2016—1342,399
2015—1352,810
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Impact Factor Trend (2018–2024)

Clarivate IF trend for Anti-Cancer Drugs

WoS Q4
1223201820192020202120222023202420252.20
Annual Impact Factor Metric
2025:2.2

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 904c281f-6367-4628-943c-0372f34dfbae
Database Updated: 2026-09-28